Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types
13.9.2024 09:00:00 EEST | Business Wire | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024.
Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial will be presented in a proffered paper session during Presidential Symposium III. Other presentations will include findings from studies evaluating Guardant360® for therapy selection in advanced breast cancer and other solid tumors, and the Guardant Infinity™ platform for response monitoring in advanced non-small cell lung cancer (NSCLC).
“Our latest data featured at ESMO further highlight the value of Guardant’s technology in precision oncology and the critical role liquid biopsy can play in informing therapy selection and treatment management across multiple tumor types,” said Craig Eagle, M.D., chief medical officer at Guardant Health. “We look forward to sharing how Guardant tests can contribute to improved outcomes across all stages of cancer care.”
Complete list of Guardant Health and collaborator presentations at ESMO 2024
Abstract | Title (Hall 6, unless otherwise noted) | Product |
Saturday, September 14 | 9:00 - 17:00 | ||
1295P | EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naïve to or following prior SRI | Guardant Infinity |
Sunday, September 15 | 9:00 - 17:00 | ||
127P | Clinical utility of circulating tumor DNA (ctDNA) next generation sequencing (NGS) to inform treatment decisions for patients (pts) with advanced solid tumors | Guardant 360 |
Monday, September 16 | 9:00 - 17:00 | ||
418P | Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer | Guardant 360 |
419P | Prevalence of gene rearrangement on ctDNA NGS and its targetability in patients with advanced breast cancer | Guardant 360 |
Monday, September 16 | 17:04 – 17:16 | ||
509O | Total neoadjuvant treatment (TNT) with non-operative management (NOM) for proficient mismatch repair locally advanced rectal cancer (pMMR LARC): first results of NO-CUT Trial Proffered Paper Session: Presidential Symposium III: Eyes to the future, Barcelona Auditorium, Hall 2 | Guardant Reveal |
The full abstracts for Guardant Health and a list of all abstracts being presented at the ESMO Congress can be found on the ESMO website.
For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook or visit Guardant on-site at booth #510.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240912788752/en/
Contacts
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Mike Weist
press@guardanthealth.com
+1 317 371 0035
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Names Dirk-Jan "DJ" van Hameren Chief Marketing Officer as Member Base Surpasses 3 Million8.7.2026 14:00:00 EEST | Press release
WHOOP, the human performance company, today named Dirk-Jan "DJ" van Hameren as Chief Marketing Officer. The appointment comes as WHOOP surpasses 3 million members worldwide after adding its latest one million members in just seven months. The former Nike Global Chief Marketing Officer and two-time Olympian joins WHOOP to help build the world's defining global brand for human performance and proactive health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708877245/en/ WHOOP Names Dirk-Jan "DJ" van Hameren (left) Chief Marketing Officer as Member Base Surpasses 3 Million Van Hameren spent more than three decades at Nike, where he rose from the mailroom at the company's European headquarters to become one of the most influential marketing leaders in the world. He served as NIKE Inc.’s Executive Vice President and Chief Marketing Officer, leading Nike's worldwide marketing organization. Van Hameren joins WHOOP as the company
Endace and Artiza Networks Partner to Deliver Cybersecurity and Defense Solutions to the Japanese Market8.7.2026 14:00:00 EEST | Press release
Endace, a leading provider of always-on packet capture, network visibility, and packet forensics solutions, and Artiza Networks, Inc. ("Artiza"), a leading provider of telecommunications test, measurement, and network assurance solutions, today announced a partnership to deliver advanced cybersecurity and defense solutions to customers in Japan. “Artiza is exactly the partner we have been looking for to satisfy demand in Japan, with the right balance of expertise, and market reach,” said Stuart Wilson, CEO of Endace. Through this partnership, Artiza will offer Endace's packet capture, network recording, and packet forensics solutions to customers in Japan, including telecommunications operators, enterprises, government agencies, defense organizations, and critical infrastructure providers. Endace's EndaceProbe Analytics Platform provides highly scalable, always-on packet capture and recording capabilities across a wide range of network environments, including enterprise networks, data
HTEC Introduces “OneLoopAi” Redefining How Enterprises Scale AI Into Production8.7.2026 13:28:00 EEST | Press release
HTEC, the global technology and engineering firm headquartered in Palo Alto, Silicon Valley, today announced it has launched HTEC OneLoopAi—a new platform and approach to managing AI execution and value realization. The platform brings real-time visibility into progress, transparency with customers, and acceleration to how AI is deployed and scaled into production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708166155/en/ HTEC, the global technology and engineering firm headquartered in Palo Alto, Silicon Valley, today announced it has launched HTEC OneLoopAi—a new platform and approach to managing AI execution and value realization. The platform brings real-time visibility into progress, transparency with customers, and acceleration to how AI is deployed and scaled into production. As enterprise investment in AI continues to rise, a critical gap has emerged: organizations lack clear visibility into how AI is being use
Robbyant Upgrades and Open-Sources LingBot-VLA 2.0 as a Next-Generation Universal Brain for Embodied AI8.7.2026 11:11:00 EEST | Press release
Robbyant, an embodied AI company within Ant Group, today announced the upgrade and open-source release of LingBot-VLA 2.0. Building upon the foundation of LingBot-VLA 1.0 released in January 2026, this next-generation vision-language-action (VLA) model delivers significant leaps in morphological generalization, degrees of freedom (DoF) support, and deployment efficiency, delivering a more advanced “universal brain” for scalable real-world robotics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707394646/en/ LingBot-VLA 2.0 supports a wide range of robot morphologies While the embodied AI industry is witnessing rapid advancements in hardware and control systems, the lack of a truly universal brain remains a primary bottleneck for industrial-scale deployment. LingBot-VLA 2.0 addresses this critical gap by dramatically expanding its pre-training data and architectural capabilities. LingBot-VLA 2.0 was pre-trained on 60,000
TetraMem and SK hynix Showcase Successful Technology Collaboration Advancing Memory-Centric AI Computing8.7.2026 11:06:00 EEST | Press release
TetraMem Inc., a leader in Analog In-Memory Computing (A-IMC) technology, and SK hynix Inc., a global leader in AI memory and semiconductor technologies, today announced the successful completion of a joint technology collaboration, highlighted by the publication of their research paper, “A Memristor-based In-Memory Computing SoC with Efficient Depthwise Convolution,” in Advanced Intelligent Systems. The work has also been selected as the cover feature of the journal, recognizing its technical innovation and potential impact on next-generation AI computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708244132/en/ The collaboration brings together SK hynix’s expertise in advanced memory technologies and TetraMem's Analog In-Memory Computing platform to explore new computing architectures capable of addressing one of artificial intelligence's most pressing challenges: reducing the energy consumption and thermal limitati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom